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OBJECTIVES This study was designed to assess prospectively changes in serum lipid profile and myocardial
perfusion with serial radionuclide single photon emission computed tomography (SPECT)
myocardial perfusion imaging (MPI) during the first six months of pravastatin therapy.
BACKGROUND Morbid coronary events occur despite statin therapy and lipid-lowering in patients with
coronary artery disease (CAD). A reliable strategy to identify responders with effective
treatment from nonresponders on statin therapy before clinical events is needed.
METHODS Rest and stress SPECT MPI and lipids were assessed serially in 25 patients (36% women)
with CAD and dyslipidemia during the first six months of pravastatin therapy.
RESULTS Total cholesterol, low-density lipoprotein cholesterol, and triglycerides declined (26%, 32%,
and 30%, respectively) by six weeks and remained reduced at six months. Mean stress
perfusion defect (summed stress score [SSS]) was severe (13.3  6.0) at baseline, showed no
change at six weeks, and improved significantly at six months (10.3  7.3, p  0.01). The
six-month study SSS improved in 11 (48%) patients, was unchanged in 10 (43%) patients,
and worsened in 2 (9%) patients. Changes in lipid levels did not reliably predict changes in
myocardial perfusion at six weeks or six months in this small pilot study.
CONCLUSIONS Serial SPECT MPI demonstrated improved stress myocardial perfusion in 48% of patients
treated for six months with pravastatin. Time course of improved myocardial perfusion during
pravastatin therapy is delayed compared to lipids. Direction and magnitude of changes in the
myocardial perfusion vary and do not correlate closely with improvements in lipids. (J Am
Coll Cardiol 2003;42:600–10) © 2003 by the American College of Cardiology Foundation
Statins modify serum lipid profiles favorably and reduce
coronary events substantially. Despite the documented ef-
fectiveness of statins, annual cardiovascular event rates in
statin-treated patients are nontrivial: 1.7% to 2.5% in
primary prevention trials (1,2) and 6.4% to 7.8% in second-
ary prevention trials (3–6). Identifying treated patients with
effectively lowered cholesterol levels who remain at risk of
coronary events remains problematic.
See page 611
The complexity and pleiotropism (7) of therapeutic re-
sponses to statin therapy suggest the potential value of
monitoring strategies more predictive than the cholesterol
profile to determine effective therapeutic response before
clinical events. An ideally predictive modality would facili-
tate timely adjustment of therapeutic strategy to yield
improved clinical outcomes in nonresponsive patients. Ra-
dionuclide single photon emission computed tomography
(SPECT) and positron emission computed tomography
(PET) myocardial perfusion imaging (MPI) provides risk
assessments in patients with known or suspected coronary
artery disease (CAD) incremental to clinical, exercise,
and/or coronary arteriographic variables (8–14). Abnormal-
ities of stress-induced coronary vasomotion identify site-
specific location of stenosis development and predict morbid
coronary events (15). Effective cholesterol-lowering im-
proves coronary endothelium-dependent vasodilation and
myocardial perfusion by invasive measurement with Dopp-
ler flow wire (16) and by PET and SPECT radionuclide
MPI (13,17–26), as well as increasing coronary artery
diameter by contrast arteriography (13,27).
Improvements in perfusion accompanying cholesterol-
lowering with serial radionuclide MPI have been reported
from 30 days (20) to 5 years (13). However, the incidence
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and time course of serial changes in myocardial perfusion,
relative to changes in lipid profile and clinical course, remain
unclear. One prior PET MPI study observed that statin-
induced augmentation of coronary flow reserve at six
months by PET MPI is delayed compared to its lipid-
lowering effects at two months (25). Given the established
lipid-lowering effect of pravastatin by six weeks and its
therapeutic effectiveness in reducing coronary events as early
as six months in the West of Scotland trial in men (1), and
in women in the Cholesterol And Recurrent Events trial
(3), the present study was designed to compare the time
course of changes in lipid levels and stress perfusion by
SPECT MPI following the initiation of pravastatin therapy.
METHODS
Patient selection. Twenty-five dyslipidemic (total choles-
terol [TC] 200 mg/dl, low-density lipoprotein [LDL]
130 mg/dl, or TC:high-density lipoprotein [HDL] 4)
patients with clinical CAD and stress-induced myocardial
perfusion defects were enrolled. Patients were excluded if
they took statin therapy during the previous two months.
With approval of the Research Subjects Review Board, the
informed consent process was performed for all patients.
Therapeutic intervention, compliance, and follow-up.
Pravastatin 40 mg qhs for six months was initiated and
compliance was assessed by monthly pill counts. Follow-up
clinical evaluation at six weeks and six months was per-
formed with lipid levels, liver function tests, and SPECT
MPI. Consideration of fibrate and niacin therapy was given
to patients with TC:HDL 4 at six weeks. All patients
were counseled closely with regard to lifestyle modification
including smoking cessation, calorie-constrained diet to
achieve ideal body weight with 30% fat calories, low
cholesterol, and at least 30 min aerobic exercise most days of
the week.
Stress testing and pre-testing medication management.
Medication usage was reviewed and beta-blockers, calcium
antagonists, nitrates, and angiotensin-converting enzyme
inhibitors were routinely held to standard therapeutic
trough levels before stress testing. Patients were instructed
to avoid caffeine consumption for 24 h before the stress test.
Exercise and adenosine stress testing was performed in 11
and 12 patients, respectively. In all but two patients the
stress testing modality was maintained for all serial imaging
(baseline, six weeks, and six months). Rate-pressure product
and Duke treadmill exercise scores were calculated in the 11
patients who underwent exercise testing.
SPECT perfusion imaging and interpretation. Routine
dual tracer (rest-thallium-201, exercise, or adenosine stress
Tc-99m-sestamibi) SPECT MPI was performed using a
dual-head SPECT DST camera (GE/SMV Medical Sys-
tems, Milwaukee, Wisconsin) with 60-s acquisitions per
stop for 32 total stops (16 stops per head) with low energy
high resolution collimators. Rest and stress perfusion images
were processed on MIRAGE PC-based software (Segami
Corp., Ellicott City, Maryland). Vertical and horizontal
spatial filtering of the back-projected data was performed
with a Butterworth low pass filter (frequency cut-off  0.4,
order  6, size  15). Consensus interpretation using
quantitative analysis of SPECT MPI data with visual
over-reading by three readers was employed. Semiquantita-
tive regional scoring was performed for stress and rest
images using the Cedars method (9,12), which employs a
five-point scale from normal (0) to absent tracer (4).
Semiquantitative regional scores were recorded in the
Nuclear Cardiology Database System using PC-based Vi-
sual Foxpro (Microsoft Corp., Seattle, Washington) with
automated calculation of summed perfusion scores (summed
rest score [SRS], summed stress score [SSS], summed
difference score [SDS]). Differences in summed perfusion
scores (SSS, SRS, and SDS) from baseline to each
follow-up period were rated as previously described (12)
(3  “improved,” 3 to 3  “no change,” 3 
“worse”). Left ventricular (LV) volume and ejection frac-
tions were obtained from the Vision PowerStation using
MultiDim (GE/SMV Medical Systems) with the use of
no-acquisition zoom, 2.5:1 intraprocessing zoom, and a
Metz Filter (3.5 full width half maximum, order 8 resulting
in a 2.7-mm pixel size) as validated in our laboratory.
To verify scintigraphic results, blinded visual analysis of
perfusion images and automated quantitative analysis of the
percent of LV hypoperfusion by defect score and global
extent on three-dimenstional topograms was performed
using the Yale Wackers-Liu CQ method (28) (Eclipse
Systems, Branford, Connecticut). The direction and mag-
nitude of changes in the myocardial perfusion and lipid
profile components were noted for each patient and for the
entire study cohort.
Statistical methods. The existence of changes in lipids
(TC, HDL, TC:HDL, LDL, triglycerides), scan readings
(SSS, SRS, SDS), and the percent of LV hypoperfusion of
defect size and global defect extent (Wackers-Liu CQ
method) across the three time periods (baseline, six weeks,
and six months) of the study was evaluated by analysis of
variance. Values found by analysis of variance to have
changed significantly within the study period were subjected
to pairwise comparison of means between each time period
using the paired t test. The power of the analysis of variance
Abbreviations and Acronyms
CAD  coronary artery disease
HDL  high-density lipoprotein
LDL  low-density lipoprotein
LV  left ventricular
MPI  myocardial perfusion imaging
PET  positron emission tomography
SDS  summed difference score
SPECT  single photon emission computed tomography
SRS  summed rest score
SSS  summed stress score
TC  total cholesterol
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and paired t tests to correctly identify deviations from the
null hypothesis was determined post-hoc using the methods
described by Zar (29). For all analyses, the significance level
was set at 5% and dropouts were excluded from consider-
ation. All analyses were conducted using SAS/STAT for
Windows (version 8.2, SAS Institute Inc., Cary, North
Carolina).
RESULTS
Preliminary evaluation of lipid, scan, and perfusion values by
analysis of variance identified statistically significant (p 
0.05) changes in the following measures during the study
period: SSS, TC, HDL, LDL, triglycerides, quantitative
percent of the LV hypoperfusion of stress defect score,
global extent, and TC:HDL ratio. On the basis of
follow-up analysis by paired t test, significant changes in
each measure were noted as follows: TC, LDL, and
triglycerides changed during the first time period (baseline
to six weeks); SSS, quantitative defect extent, and HDL
changed during the second time period (six weeks to six
months); and TC:HDL changed during both time periods.
Clinical characteristics of the patient population. Of the
25 patients (9 women; 36%) who enrolled in the trial, 23
(92%) completed the entire study. Two study dropouts
excluded from analysis included a man referred for coronary
artery bypass graft surgery because of decreased perfusion at
six weeks and a woman with improved perfusion at six
weeks who failed subsequent follow-up. Baseline clinical
characteristics of the 23 patients completing the study are
summarized in Table 1. Eleven of the 23 recruited patients
had a new diagnosis of CAD. Medications taken at base-
line, six weeks, and six months are listed in Table 2. With
the exception of three patients who received angiotensin-
converting enzyme inhibitors and five patients who received
niacin between six weeks and six months, most medication
changes were completed before the six-week visit.
Compliance and tolerance of pravastatin. On the basis of
pill counts, mean compliance with the pravastatin regimen
was 95% (minimum 91.1%). No patient experienced
significant elevations (2  upper normal limit) in liver
function tests, or reported myalgia, fatigue, or other adverse
effects attributable to pravastatin.
Stress testing. Eleven of the 23 study patients underwent
provocative stress testing with an exercise protocol. Angina
during exercise tolerance testing (ETT) was reported by
three patients at baseline, one patient at six weeks, and none
at six months. Group mean rate-pressure product at baseline
(28,222 4,752) and Duke treadmill exercise score (0.14
10.91) were unchanged at six weeks and six months.
Lipid profile and SPECT MPI during pravastatin treat-
ment. Lipid profile, the number of patients actively smok-
ing and with hypertension, and SPECT MPI values at each
time period are presented in Table 3. Statistically significant
reductions were noted at six weeks for LDL (32%), TC
(26%), and triglycerides (30%), which persisted at six
months. Statistically significant changes were also noted at
six months for HDL (15% increase), SSS (23% decrease),
SDS (40% decrease), and quantitative defect size and
topographic extent percent of LV hypoperfusion (35%
decrease) (Figs. 1D to 2B), with no change at six weeks.
The TC:HDL declined 25% from baseline to six weeks and
declined 32% from six weeks to six months. No significant
changes in SRS, quantitative resting perfusion defect size or
extent, left ventricular ejection fraction, or left ventricular
end-systolic volume index were noted at six weeks or six
months (Table 3).
Average baseline SSS was severe (13.3  6; mean  SD)
and declined to a moderate-average score (10.3 7.3) at six
months. Of the 23 patients completing the study, SSS
declined in 11 (48%) patients, which included complete
normalization (4) in 5 (22%) patients; SSS remained
Table 1. Baseline Clinical Characteristics of 23 Patients
Completing the Study
Coronary risk factors
Age, 59.9  9.5 yrs
History of MI, n  9
Diabetes, n  5
Hypertension, n  12
LDL 130 mg/dl, n  11; TC 200 mg/dl, n  17;
TC:HDL 4.0 mg/dl, n  19
Low HDL (35 mg/dl in men or 45 mg/dl in women mg/dl),
n  14
Smoking: history of smoking, n  10; active smokers, n  5
Number of coronary risk factors  4.7  1.5
Indications for index SPECT MPI study
Chest pain or exertional dyspnea, n  10
Postinfarction risk stratification, n  6
Hemodynamic assessment of known coronary artery disease, n  3
Evaluation of an abnormal ECG, n  2
Preoperative risk stratification, n  2
Coronary angiography, n  8
Single-vessel disease, n  4
Multivessel disease, n  4
2-vessel disease, n  2
3-vessel disease, n  2
Coronary end points during study of the original 25-patient cohort
MI, n  1
Coronary artery bypass graft surgery, n  1
Unstable angina, PCI, cardiac death, n  0
ECG  electrocardiogram; HDL  high-density lipoprotein; LDL  low-density
lipoprotein; MI  myocardial infarction; MPI  myocardial perfusion imaging;
PCI  percutaneous coronary intervention; SPECT  single photon emission
computed tomography; TC  total cholesterol.
Table 2. Medications Taken at Baseline, Six Weeks, and
Six Months
Medication Baseline 6 Weeks 6 Months
Aspirin 15 21 22
Beta-blocker 12 18 19
ACE inhibitor 7 8 11
A2 receptor blocker 0 1 1
Calcium blocker 4 4 3
Estrogen 3 3 3
Nitrate 4 2 2
Niacin 0 1 6
ACE  angiotensin-converting enzyme.
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unchanged in 10 (43%) patients and increased in 2 (9%)
patients (Table 4). Four of 23 (17%) patients had worse SSS
at six weeks than at six months. One of these four patients
had a history of prior Q-wave myocardial infarction and
developed recurrent infarction with deepening of Q waves
in two of the inferior electrocardiographic leads before six
weeks of therapy with pravastatin. Asymptomatic progres-
sion of the scan defects was noted in the other three patients
at six weeks. Six-month scans of these four patients revealed
improvement in one patient, deterioration in one patient,
and no change in two patients as compared with six-week
scans. The resting study was unchanged in 12 patients
(52%), improved in 6 (26%) patients, and worse in 4 (17%)
patients. The SDS was better in 14 (61%) patients, un-
changed in 5 (22%) patients, and worse in 4 (17%) patients
(Table 4).
The direction and magnitude of changes in the myocar-
dial perfusion were variable and did not correlate with
improvement of the lipid profile. Twenty-one of 23 patients
showed improved LDL levels at six months; however, stress
perfusion improved (reduced SSS 3) in only 9 of these
patients. Of two patients in the study who failed to show a
significant reduction of LDL cholesterol by six months,
stress perfusion improved significantly (reduced SSS 3) in
each. Responses of SSS to pravastatin therapy with either
exercise or adenosine stress were similar.
Other medical therapy and changes of myocardial perfu-
sion. Medication changes between six weeks and six
months did not correlate with perfusion changes observed.
Of the three patients started on angiotensin-converting
enzyme inhibitor therapy, one patient showed improved
SSS, one patient worsened, and one patient remained
unchanged. The HDL increased at six months, but not at
six weeks, potentially because of the addition of niacin after
six weeks in five patients. However, SSS improved in two of
these patients and remained unchanged in the other three.
Thus, niacin-associated improvement in HDL did not
account for all the changes in SSS between six weeks and six
months.
DISCUSSION
Our laboratory first reported statin-induced improvements
in stress myocardial perfusion by SPECT MPI in 1997 (17)
following seminal reports of similar improvements with
cholesterol-lowering therapy by PET MPI by Gould et al.
(13,18) and Czernin et al. (19). Improvements in radionu-
clide MPI with lipid-lowering, including lifestyle changes
and statins, have subsequently been confirmed indepen-
dently by both PET (20,24–26) and SPECT MPI (21,23).
Assessment of treatment response to statins by cholesterol
levels appears inadequate, as up to 7.8% of patients with
improved lipids on statin therapy experience coronary events
in randomized controlled trials (1–6). Beyond cholesterol-
lowering, radionuclide tomographic MPI may identify ef-
fective statin treatment response associated with improve-
ment of abnormalities of endothelial function associated
with dyslipidemia or CAD (15–26,30,31) as recently re-
viewed (22).
The current study is the first prospective serial monitor-
ing trial using SPECT MPI to assess both early and late
changes in myocardial perfusion and the lipid profile during
the first six months of statin therapy. The principal finding
of this study is pravastatin reduced abnormalities of stress
perfusion (SSS, SDS, quantitative defect extent) by radio-
nuclide SPECT MPI at six months but not six weeks in
compliant dyslipidemic patients with CAD. In contrast,
pravastatin reduced serum levels of TC, LDL cholesterol,
and triglycerides by six weeks, and these reductions persisted
at similar levels at six months. Despite a 32% reduction in
LDL for the study group, the direction and magnitude of
changes in stress myocardial perfusion varied widely. No
change of group mean resting perfusion (SRS) was observed
during the study, similar to prior SPECT (21) and PET
(25) monitoring studies during statin therapy. Differences in
MPI technique, study population, time course, degree of
resting endothelial dysfunction, definition, or degree of
dyslipidemia may account for the lack of alteration of resting
perfusion observed in our study. As expected, no changes of
left ventricular ejection fraction, end-diastolic volume index,
or end-systolic volume index were observed during this
six-month study.
The results contribute to our current understanding that:
1) scan findings parallel the time course of earliest docu-
mented coronary event reduction in the randomized clinical
trials by pravastatin (1,3), rather than the earlier reduction
of lipid changes that occurred at six weeks; 2) normalization
Table 3. Single Photon Emission Computed Tomography
Myocardial Perfusion Imaging, Lipid Profile Values, and
Coronary Risk Factors During Pravastatin Therapy
Baseline 6 Weeks 6 Months
TC (mg/dl) 220  37 163  23* 171  27*
HDL cholesterol (mg/dl) 41  12 42  11 47  11*†
TC:HDL ratio 5.60  1.30 4.18  1.08* 3.81  0.95*†
LDL cholesterol (mg/dl) 134  31 91  18* 96  23*
Triglycerides (mg/dl) 232  128 162  59* 154  68*
SSS 13.3  6.0 12.3  7.2 10.3  7.3*
SRS 5.0  4.1 5.8  4.6 5.3  4.7
SDS 8.3  4.6 6.5  7.2 5.0  8.0*
Extent (% LV) hypoperfusion 25.5  13.7 24.5  14.1 16.6  13.8*
LV volume and function
LVEDVI (ml/m2) 84  22 86  21 81  18
LVESVI (ml/m2) 40  16 42  14 38  13
LVSVI (ml/m2) 44  10 44  10 43  8
LVEF (%) 54  8 52  8 53  7
Active smokers (n) 5 3 3
SBP 140 mm Hg or
DBP 90 mm Hg (n)
7 5 6
*Significant t test (p  0.05) for comparison to baseline value (mean  SD);
†significant t test (p  0.05) for comparison to 6-week value (mean  SD).
DBP diastolic blood pressure; LV left ventricular; LVEDVI left ventricular
end-diastolic volume index; LVEF  left ventricular ejection fraction; LVESVI 
left ventricular end-systolic volume index; LVSVI  left ventricular stroke volume
index; SBP  systolic blood pressure; SDS  summed difference score; SRS 
summed rest score; SSS  summed stress score. Other abbreviations as in Table 1.
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of stress scans, which is known to be associated with
improved prognosis during anti-ischemic therapy (32,33),
and an extremely low rate of subsequent coronary events
reported for patients with normal scans (8,9,11,12,14,34),
was observed in 22% of patients on statin therapy; and 3)
changes in the direction and magnitude of serum lipids
levels did not closely parallel the improvement of stress
perfusion in individual patients.
Figure 1. (A to C) Single photon emission computed tomography myocardial perfusion imaging orthogonal plane images before pravastatin therapy
(baseline), at six weeks, and at six months of pravastatin therapy in a typical patient with reduced summed stress score by six months. Consistent with
randomized controlled trials, pravastatin 40 mg was administered on a non-dose titrated basis. Stress perfusion defect size declined in 11 (48%) and was
stable in 10 (43%) of 23 patients completing the trial. Continued on next page.
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Our findings confirm a prior PET MPI study showing
statin-induced improvement of stress perfusion at six
months follows earlier lipid-lowering at two months and
appeared unrelated to the amount of lipid-lowering (25).
Statin-induced upregulation of endothelial nitric oxide syn-
thase by Rho GTPase is an important mechanism of
improved endothelial function and myocardial perfusion
regulated downstream from cholesterol-lowering HMG-
CoA reductase pathway (35). Additionally, numerous pleio-
tropic effects of statins appear to contribute to their thera-
peutic effectiveness (7,36).
Potential study limitations. Medications in addition to
pravastatin after the baseline SPECT MPI study might
have contributed to the scan changes; however, we did not
observe any response trend in patients with altered medica-
tion regimen. Only modest absolute changes in myocardial
Figure 1 Continued on next page.
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perfusion were noted during this six-month study. How-
ever, these findings are consistent with prior reports of
disproportionately greater effects of statin therapy on myo-
cardial perfusion and cardiac events than on modest regres-
sion of coronary stenoses in randomized arteriographic trials
(13). Because of limited sample size, this study may have
insufficient power to detect minor or short-term changes in
SPECT MPI variables and their correlation with serum
lipid levels. Post-hoc analyses indicate a power in excess of
80% for all changes in lipid and scan values (baseline
compared to six months) with the exception of HDL (71%).
Lack of placebo arm is a potential weakness, but such trial
design is considered unethical in the current era of docu-
mented effectiveness of statins in patients with CAD
(2–4,6). Open-label study design might lead to scan inter-
pretation bias; however, re-analyses of scans without knowl-
edge of their chronologic order (data not shown) and
automated quantitative analyses (Figs. 1B and 2B) have
Figure 1 Continued on next page.
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Figure 1 Continued. (D) Automated quantitative analyses of defect (percent of left ventricular hypoperfusion) size (left images) and global extent (right images) at baseline, six
weeks, and six months of pravastatin therapy. Quantitative analyses verified improved average stress perfusion by six months in the study population.
607
JACC
Vol.42,No.4,2003
Schw
artz
et
al.
August20,2003:600–10
Pravastatin
CAD
Regression
SPECT
M
onitoring
Trial
Figure 2. (A) Single photon emission computed tomography (SPECT) summed stress score (SSS) and summed difference score (SDS) (SDS  SSS  summed rest score [SRS]) of myocardial perfusion
abnormalities at baseline and six months are compared. Significant reductions in these perfusion indices were observed. In contrast, SSS was not reduced at six weeks. The SRS did not change during the
study (see text). Lines track individual patient values from baseline to the six-month study. Continued on next page.
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confirmed the results. Serial changes of high sensitivity
C-reactive protein and other inflammatory markers poten-
tially modulated by statins (36) were not assessed in the
current study.
Conclusions. In compliant dyslipidemic patients with ab-
normal baseline myocardial perfusion by SPECT MPI,
pravastatin therapy improved stress perfusion in 48% of the
study patients by six months but not by six weeks. Divergent
responses to pravastatin of lipid and scintigraphic parame-
ters were observed and variability of responses was substan-
tial. Scan improvement did not correlate with the magni-
tude of LDL reduction in this small pilot study.
Serial monitoring of stress radionuclide PET and
SPECT perfusion abnormalities during pravastatin therapy
may identify substantial variability in the presence and
magnitude of therapeutic response not reflected by the
serum lipid response. Whether patients who fail to improve
stress myocardial perfusion despite appropriate lipid-
lowering on statin therapy are at increased risk of coronary
events is not yet known. The results of the current study
support longer term prospective investigation of serial
changes in lipids and radionuclide MPI during statin
therapy and correlation with clinical outcomes to assess the
time course and characteristics of effective therapeutic re-
sponse. This combined lipid and radionuclide tomographic
perfusion-guided approach may improve assessment of the
residual risk on statin therapy and facilitate optimal utiliza-
tion of medical and revascularization therapies.
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